IDT Australia Limited (ASX:IDT) is a Melbourne-based contract development and Manufacturing organisation (CDMO) that provides specialist pharmaceutical manufacturing services across three core verticals: active pharmaceutical ingredients (API), specialty oral dose forms, and advanced therapies. The company serves both domestic and international pharmaceutical clients and has been executing a strategic reset designed to improve Operating Leverage and move the Business toward profitability.

Recent Development

On 20 August 2026, IDT Australia announced significantly improved FY26 results, with EBITDA improving 85% year-on-year to negative $922,000, and ordinary Revenue from its three core verticals rising 16.5% to $16.8 million. The composition of revenue shifted during the year, with API growing to 32.3% of revenue (from 29.1%), Specialty Orals growing to 32.5% (from 24.9%), while Advanced Therapies declined to 35.2% from 45.9%. Total revenue including disbursements and other income was $20.4 million. The company stated it is on track to deliver positive EBITDA in FY27, underpinned by a growing global client base and increasing Demand for its specialist CDMO capabilities. IDT has established a three-year $50 million revenue target, supported by expansion of existing local and international strategic clients and customer acquisitions. A new $7 million Capital Investment — to be debt-funded through an existing Facility — has been announced to install a new sterile line and upgrade solid oral manufacturing capabilities, with the aim of bolstering IDT's competitive position and pricing power.

Sector Context

The global CDMO market is experiencing strong demand growth, driven by increasing pharmaceutical outsourcing, the proliferation of complex biological and advanced therapy medicinal products (ATMPs), and a broad trend toward specialisation in drug manufacturing. Australia has niche advantages in advanced therapies and API manufacturing, and IDT's specialist capabilities position it to capture growing demand from both domestic and international pharma clients seeking compliant, high-quality manufacturing partners in a Western jurisdiction.

Risks and Uncertainties

IDT remains loss-making at the EBITDA level in FY26, and the path to positive EBITDA in FY27 requires continued revenue growth and disciplined cost management. The $7 million capital investment, while strategically sound, adds Debt to the Balance Sheet and creates commissioning and validation risk if the new sterile line takes longer than expected to reach commercial production. The Advanced Therapies segment — which has the highest Margin potential — is declining as a proportion of revenue, which warrants monitoring. Client concentration risk in a specialist CDMO business is also worth noting.

Catalysts to Watch

The most closely watched near-term development is IDT's delivery of positive EBITDA in FY27, which management has guided as an expected outcome. Any announcement of new long-term contracts with international pharmaceutical clients — particularly for sterile manufacturing or advanced therapies — would be significant. Progress on the installation of the new sterile line and its validation for commercial use will also be an important milestone. Updates on progress toward the three-year $50 million revenue target will provide the clearest indication of the strategic reset's trajectory.

Bottom Line

IDT Australia has made meaningful progress in its strategic reset — EBITDA improved 85% in FY26 and the company appears genuinely close to the positive EBITDA threshold. The $7 million manufacturing investment signals management confidence in the forward revenue pipeline. For investors seeking healthcare sector exposure in a specialist, niche-capability CDMO with a credible turnaround trajectory, IDT warrants attention heading into FY27.